Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2014-206404 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2014-206404 25739829!�!25739829 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25739829&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25739829.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Ann+Rheum+Dis 2015 ; 74 (6): 1178-82 Nephropedia Template TP {{tp|p=25739829|t=2015. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial |pdf=|usr=}}{{25739829}} gab.com Text Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=25739829 #FOAvip OBJECTIVES: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown. METHODS: Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal involvement were randomised, 3:1, to glucocorticoids plus either rituximab (375 mg/m(2)/weekx4) with two intravenous cyclophosphamide pulses (n=33, rituximab group), or intravenous cyclophosphamide for 3-6 months followed by azathioprine (n=11, control group). RESULTS: The primary end point at 24 months was a composite of death, end-stage renal disease and relapse, which occurred in 14/33 in the rituximab group (42%) and 4/11 in the control group (36%) (p=1.00). After remission induction treatment all patients in the rituximab group achieved complete B cell depletion and during subsequent follow-up, 23/33 (70%) had B cell return. Relapses occurred in seven in the rituximab group (21%) and two in the control group (18%) (p=1.00). All relapses in the rituximab group occurred after B cell return. CONCLUSIONS: At 24 months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups. In the rituximab group, B cell return was associated with relapse. TRIAL REGISTRATION NUMBER: ISRCTN28528813. Twit Text FOAVip Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=25739829 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25739829 #FOAvip English Wikipedia <ref>{{Cite pmid|25739829}}</ref> Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial #MMPMID25739829 Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR Ann Rheum Dis 2015[Jun]; 74 (6): 1178-82 PMID25739829show ga OBJECTIVES: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown. METHODS: Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal involvement were randomised, 3:1, to glucocorticoids plus either rituximab (375 mg/m(2)/weekx4) with two intravenous cyclophosphamide pulses (n=33, rituximab group), or intravenous cyclophosphamide for 3-6 months followed by azathioprine (n=11, control group). RESULTS: The primary end point at 24 months was a composite of death, end-stage renal disease and relapse, which occurred in 14/33 in the rituximab group (42%) and 4/11 in the control group (36%) (p=1.00). After remission induction treatment all patients in the rituximab group achieved complete B cell depletion and during subsequent follow-up, 23/33 (70%) had B cell return. Relapses occurred in seven in the rituximab group (21%) and two in the control group (18%) (p=1.00). All relapses in the rituximab group occurred after B cell return. CONCLUSIONS: At 24 months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups. In the rituximab group, B cell return was associated with relapse. TRIAL REGISTRATION NUMBER: ISRCTN28528813. |Aged[MESH] |Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications/drug therapy/immunology[MESH] |Antibodies, Monoclonal, Murine-Derived/*therapeutic use[MESH] |Azathioprine/*therapeutic use[MESH] |B-Lymphocytes/cytology[MESH] |Cyclophosphamide/*therapeutic use[MESH] |Disease Progression[MESH] |Disease-Free Survival[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Glucocorticoids/*therapeutic use[MESH] |Granulomatosis with Polyangiitis/complications/*drug therapy/immunology[MESH] |Humans[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Kidney Failure, Chronic/etiology[MESH] |Lymphocyte Count[MESH] |Male[MESH] |Microscopic Polyangiitis/complications/*drug therapy/immunology[MESH] |Middle Aged[MESH] |Renal Insufficiency, Chronic/*drug therapy/etiology/immunology[MESH]Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis:(epmc).pdf DeepDyve Pubget Overpricing